Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda clinical programs — 1179 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Cambridge, USA
Founded
1993
Employees
1,617
Programs
1179
Drugs
359
Patents
1436
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Takeda projects

1,179 ClinicalTrials.gov programs sponsored by Takeda.

Takeda has 1,179 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

1,179 programs

Clinical programs

Page 4 of 25

  1. Lifestyle modification

    Takeda

    Type 2 Diabetes

    phase 3 other completed

    1 trial

  2. Lifitegrast

    Takeda

    Dry Eye Disease

    phase 3 small molecule completed

    3 trials

  3. Lifitegrast

    Takeda

    Keratoconjunctivitis Sicca

    phase 3 small molecule completed

    1 trial

  4. Lisdexamfetamine Dimesylate (LDX)

    Takeda

    ADHD

    phase 3 small molecule completed

    3 trials

  5. Lisdexamfetamine dimesylate

    Takeda

    Binge Eating Disorder

    phase 3 small molecule completed

    2 trials

  6. Low-dose rtPA

    Takeda

    Ischemic Stroke

    phase 3 small molecule completed

    1 trial

  7. Lu AA21004

    Takeda

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  8. Lubiprostone

    Takeda

    Irritable Bowel Syndrome With Constipation

    phase 3 small molecule completed

    1 trial

  9. Lubiprostone

    Takeda

    Constipation - Functional

    phase 3 small molecule completed

    1 trial

  10. MLN0002-3024

    Takeda

    Moderately to severely active Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  11. MLN0002-3025

    Takeda

    Moderately to severely active Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  12. MLN0002-3029

    Takeda

    Active Ulcerative Colitis (UC) or Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  13. MMX Mesalamine/Mesalazine (Low Dose)

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  14. MOVIPREP

    Takeda

    Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.

    phase 3 small molecule completed

    1 trial

  15. Magnesium Pantoprazole

    Takeda

    GERD

    phase 3 small molecule completed

    1 trial

  16. Magnesium Pantoprazole 20 mg

    Takeda

    Gastric pH Control

    phase 3 small molecule terminated

    1 trial

  17. Maribavir

    Takeda

    Cytomegalovirus (CMV)

    phase 3 small molecule completed

    6 trials

  18. Matching Placebo for TAK-279, ZASOCITINIB

    Takeda

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  19. Metformin on top of intensive insulin therapy

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  20. Mezagitamab

    Takeda

    Chronic Primary Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  21. Mezagitamab

    Takeda

    Immune Thrombocytopenic Purpura (ITP)

    phase 3 small molecule active

    2 trials

  22. Mezagitamab, Placebo matching for Mezagitamab

    Takeda

    Chronic Primary Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  23. Mixed salts of a single-entity amphetamine

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  24. Mixed salts of a single-entity amphetamine (ADDERALL XR)

    Takeda

    ADHD

    phase 3 small molecule completed

    1 trial

  25. Motesanib

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule terminated

    1 trial

  26. MyelomaXIV

    Takeda

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  27. NE-58095 IR

    Takeda

    Involutional Osteoporosis

    phase 3 small molecule completed

    1 trial

  28. NPSP558

    Takeda

    Hypoparathyroidism

    phase 3 small molecule completed

    3 trials

  29. OBI-1

    Takeda

    Hemophilia A

    phase 3 mab terminated

    1 trial

  30. OBI-1

    Takeda

    Acquired Hemophilia A

    phase 3 mab completed

    1 trial

  31. Ontamalimab

    Takeda

    Crohn's Disease

    phase 3 mab terminated

    3 trials

  32. Ontamalimab

    Takeda

    Ulcerative Colitis

    phase 3 small molecule terminated

    3 trials

  33. Oral Budesonide Suspension (OBS)

    Takeda

    Eosinophilic Esophagitis (EoE)

    phase 3 small molecule completed

    2 trials

  34. Orteronel

    Takeda

    Prostate Cancer

    phase 3 small molecule completed

    3 trials

  35. PEGylated Recombinant Factor VIII

    Takeda

    Hemophilia A

    phase 3 mab completed

    2 trials

  36. PEGylated Recombinant factor VIII (rFVIII)

    Takeda

    Hemophilia A

    phase 3 mab completed

    1 trial

  37. PTH/Calcium

    Takeda

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  38. Panitumumab-3001

    Takeda

    Colorectal Cancer

    phase 3 small molecule completed

    1 trial

  39. Pantoprazole

    Takeda

    Gastroesophageal Reflux Disease (GERD)

    phase 3 small molecule completed

    2 trials

  40. Pantoprazole

    Takeda

    GERD

    phase 3 small molecule completed

    1 trial

  41. Parathyroid Hormone (PTH)

    Takeda

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  42. Parathyroid hormone

    Takeda

    Disruption or Dehiscence of Closure of Sternum or Sternotomy

    phase 3 small molecule completed

    1 trial

  43. Pioglitazone

    Takeda

    HIV-Associated Lipodystrophy Syndrome

    phase 3 small molecule terminated

    1 trial

  44. Pioglitazone

    Takeda

    Impaired Glucose Tolerance

    phase 3 small molecule completed

    1 trial

  45. Pioglitazone

    Takeda

    Mild Cognitive Impairment Due to Alzheimer's Disease

    phase 3 small molecule terminated

    2 trials

  46. Pioglitazone and Azilsartan

    Takeda

    Type 2 Diabetes

    phase 3 small molecule terminated

    1 trial

  47. Pioglitazone and Glimepiride

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  48. Pioglitazone-Azilsartan

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Takeda have?

1,179 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.